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ABSTRACT
Although current dialysis techniques have transformed acute
and chronic renal failure fromuniformly fatal clinical disorders
into treatable diseases, these therapies replace only the water
and solute clearance function of the kidney and have reached a
point where little further therapeutic improvement can be
anticipated. In addition to their metabolic and endocrine func-
tions, renal tubule cells presumably play an important role in
the systemic inflammatory balance by participating in the com-
plex and dynamic network of leukocyte action and pro- and
anti-inflammatory cytokines. Loss of this function may result
in a propensity to develop systemic inflammatory response syn-
drome (SIRS), multiorgan dysfunction, and a high risk of
death in acute kidney injury (AKI), and may relate to chronic
inflammatory state in end-stage renal disease (ESRD). A renal
tubule cell assist device (RAD) containing animal or human
renal tubule cells has been recently developed with the purpose
of integrating the functions of tubule cells with the filtration
function of current dialysis to offer a more complete renal
replacement therapy. The viability and functionality of this
device were confirmed in in vitro experiments and large animal
studies, and recently theRAD’s clinical therapeutic benefit was
demonstrated with a series of FDA-approved human trials.
Another novel synthetic membrane extracorporeal device that
binds and inhibits circulating leukocytes has been developed
with the purpose of reducing microvascular damage promoted
primarily via activated circulating leukocytes in AKI and
SIRS. This device, called a selective cytopheretic inhibitory
device, mimics immunomodulation and duplicates RAD effi-
ciency in preliminary studies. Both devices may become com-
prehensive treatments, replacing full renal function and
correcting inflammatory imbalance in patients with acute and
chronic renal disorders.
Acute kidney injury (AKI) affects up to 200,000 peo-
ple in the United States annually, and approximately
5% of all long-term hospital patients. The development
of AKI in a hospitalized patient results in a five- to eight-
fold higher risk of death (1). The cause of death subse-
quent to AKI is generally the development of systemic
inflammatory response syndrome (SIRS), frequently
secondary to bacterial infection or sepsis, resulting in
cardiovascular collapse and ischemic damage to vital
organs, culminating in multiple organ failure (MOF; 2).
An estimated 700,000 cases of sepsis occur each year,
resulting in more than 210,000 deaths in the United
States (3). The combination of AKI and sepsis is associ-
ated with a 70%mortality rate, as compared with a 4%
mortality rate among patients withAKI alone (4).
Current therapy for AKI is predominantly supportive
in nature. The therapeutic goals are the maintenance of
fluid and electrolyte balance, adequate nutrition, and
treatment of infection and uremiawhen they are present.
Uremia is treated with dialysis, either intermittent he-
modialysis or continuous hemofiltration. Although this
approach has substantially impacted this disease process
over the last 40 years, patients with clinically severe AKI
still have an exceedingly high mortality of >50% (5).
This high mortality, despite normal electrolyte balance
and improvement in the uremic state, is because of the
propensity of these patients to develop SIRS, most com-
monly secondary to bacterial sepsis, with resultingMOF
from cardiovascular collapse and ischemia (6).
Limited Success of Current Dialysis Therapies
Current dialysis therapies are suboptimal for both
AKI and end-stage renal disease (ESRD). These thera-
pies do not meet the medical need for treatment of
reducing mortality from AKI. Even in ESRD, the out-
comes of patients receiving chronic dialysis therapy are
still disappointing, with an annual mortality exceeding
25%, on average, and a drastically shortened life expec-
tancy of only 5 years (7). Several groups have reported
that the survival of critically ill patients with AKI could
be improved by intensifying the dose of renal replace-
ment therapy (8–10), but the initial excitement generated
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by these reports has waned following studies demon-
strating that dialysis dose is not closely related to out-
comes (11–13). Recent work by the VA ⁄NIH Acute
Renal Failure Trial Network intensified the skepticism
(14). Regarding ESRD, current data from two large ran-
domized controlled trials in ESRD, the Hemodialysis
(HEMO) Study (15) and the ADEMEX (ADEquacy of
PD in MEXico) Study in peritoneal dialysis (16), have
also failed to show a survival benefit from increased dial-
ysis dose. These results suggest that current therapies
focusing only on fluid and small- and middle-molecule
solute clearance are limited in their ability to further
influence outcomes.
The kidney is notmerely a filtration organ. It also pro-
vides important transport, homeostatic, metabolic, and
endocrinologic functions. The transport function of the
kidney includes not only water and solute homeostasis
but the important reclamation of metabolic substrates,
including essential amino acids and glucose. The kidney
serves as a critically important metabolic organ, synthe-
sizing glutathione (GSH) and free-radical scavenging
enzymes and providing gluconeogenic and ammonio-
genic capabilities (17,18). Catabolism of low-molecular-
weight proteins, including peptide hormones, cytokines,
and growth factors, is also accomplished by the kidney
(19), and this organ has an important hormonal function
with the production and regulation of erythropoietin,
vitamin D, and multiple cytokines critical to inflamma-
tion and immunologic regulation (20). The propensity of
patients with acute renal failure (ARF) to develop SIRS
and sepsis suggests the renal tubular cell has a critical
immunomodulatory role under stress states (2,21).
For these reasons, ‘‘renal replacement therapy’’ is an
inappropriate description for current dialysis treatments,
which replace only the filtration function of the failed
kidney without addressing its metabolic, endocrinologic,
and immunologic roles. It is also not optimal to treat
simply the volume, electrolyte, and uremic problems,
and to focus only on kidney injury and recovery per se in
situations in whichAKI is combined with sepsis or SIRS
and interacts with distant organs such as the lung and
heart.
Less Recognized Role of the Kidney:
Immunoregulation
The immunoregulatory role of the mammalian renal
proximal tubule cells is under appreciated. The kidney is
derived embryologically from dorsal mesoderm, a col-
lection of cells also important in the development of
bone marrow stem cells (22). Phylogenetically, in bony
fish and amphibians without lymph systems, the kidney
is themajor antibody-producing organ (22) and, not sur-
prisingly, mammalian renal proximal tubule cells are
immunologically active. They are antigen-presenting
cells (23) that have costimulatory molecules (24) that
synthesize and process a variety of inflammatory cyto-
kines (25,26).
GSH is resynthesized and returned to the systemic cir-
culation by the proximal tubule cells (27). These cells are
also the major source of synthesis of antioxidant GSH-
related enzymes (28). A variety of studies have clearly
shown that excessive free-radical generation contributes
to vascular and tissue damage in sepsis, which triggers a
complex series of coagulation, complement, and cyto-
kine cascades to defend against bacterial invasion
(28,29). The loss of both GSH synthetic function and
production of key free-radical scavenging enzymes in
renal failure undoubtedly increases the risk of sepsis syn-
drome (28). The key role of the kidney in this GSH regu-
latory pathway is exemplified by the fact that renal
failure patients have severely low plasma levels of GSH
and its peroxidases (30), and therefore are at increased
risk for oxidative stress, especially in bacterial infection.
1,25-dihydroxyvitamin D3 (vitamin D3) plays an
important role in the regulation of the immune system
(31,32). The immune system is recognized as a target
tissue of this important hormone. High-affinity recep-
tors are found in peripheral blood lymphocytes and
thymocytes, and vitamin D deficiency impairs cell-medi-
ated immunity (31). Neutrophils from patients with
vitaminDdeficiency have abnormalmotility and phago-
cytic ability (32). Administration of vitamin D3 to
patients on hemodialysis restores mitogen-stimulated
T-cell responses to normal (33). A critical role of cyto-
solic calcium in the oxidative burst of granulocytes has
been acknowledged (34).
The roles of the renal tubular cells in GSH metabo-
lism, synthesis of GSH peroxidase and free-radical scav-
enging enzymes (17), regulation of vitamin D, and
production and catabolism of multiple cytokines (20)
are critical to immunoregulation to maintain tissue
integrity and host defense under stress conditions (21).
AKI and ESRD as Systemic Inflammatory
Diseases
AKI, or acute tubular necrosis (ATN), which results
in the loss of the kidney’s presumed immunoregulatory
function, results in a propensity to develop SIRS, sepsis,
MOF, and a high risk of death because of systemic
immunologic or inflammatory imbalance caused by
kidney cell injury or necrosis. Activation and release of
inflammatory proteins from circulating activated
leukocytes and imbalance between pro- and anti-
inflammatory proteins are provoked and aggravated
by kidney cell injury and possibly by dialysis. These
conditions play a central role in the proinflammatory
state inAKIwith SIRS and ⁄orMOF.
SIRS is a catastrophic sequela of a variety of clinical
insults and is usually present with AKI. In the past dec-
ade, a large amount of data has provided new insights
into the inflammatory response that seems to underlie
the MOF syndrome. There are now data linking patient
outcome to initial plasma levels of tumor necrosis factor
(TNF)-a, interleukin (IL)-6, and other proinflammatory
cytokines (35–37). Septic shock is an acute syndrome
that is characterized by hypotension, coagulopathy, and
eventual MOF primarily because of ischemic tissue
injury. This disorder is associated with dramatic eleva-
tions in inflammatory cytokines, including TNF-a, IL-
1b, IL-6, IL-8, and interferon-c (17). This reactive and
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uncontrolled inflammatory response results in the
adverse hemodynamic and metabolic disturbances in
septic shock. If this balance between pro- and anti-
inflammatory mediators is lost, the patient may proceed
to cardiovascular collapse if proinflammatory processes
are excessive, or develop profound immunosuppression
with increased risk of recurrent or continuing infection if
the anti-inflammatory cascade overreacts (36,37).
ESRD is recognized as a disease associated with
chronic inflammation that predisposes patients to car-
diovascular diseases and acute infectious complications,
the two most common causes of death, despite adequate
hemodialysis. Clinically, the chronic inflammatory state
in ESRD patients, which is independent of dialyzer
membrane activation and clearance, is represented by
elevated levels of C-reactive protein and proinflammato-
ry cytokines, including IL-1, IL-6, and TNF, equivalent
to a chronic proinflammatory state (38,39). All these
parameters are associated with enhanced mortality in
ESRD patients and might have many causes, including
the clearance of GSH, negative nitrogen balance and
energy loss in the clearance of peptides and amino acids,
loss of tubular cell function in oxidative deamination,
gluconeogenesis, and loss of cytokine and hormonemet-
abolic activity in the kidney.
Because renal tubule cells may play an important role
in the systemic inflammatory balance by participating in
the complex and dynamic network of leukocyte action
and pro- and anti-inflammatory cytokines, our research
group turned its attention to the effort to replace this
immunomodulatory function in addition to the kidney’s
filtration, metabolic, and endocrine functions. Our focus
is not confined to the kidney but extends to the whole
body.
Renal Bio-Replacement Therapy in AKI
and SIRS
The replacement of the functions of renal tubule cells
during the AKI episode in conjunction with hemofiltra-
tion provides more complete renal replacement therapy
as compared with the ‘‘partial’’ replacement therapy of
current dialysis treatments (Fig. 1). The addition of met-
abolic activity, such as ammoniogenesis and GSH recla-
mation, activation of vitamin D3, low levels of which
seem to correlate with high mortality rates in hospital-
ized patients (40), immunoregulatory support, and cyto-
kine homeostasis may replace important physiologic
activities to change the current natural history of this dis-
ease process (Fig. 2; 21). We have developed an extra-
corporeal device utilizing a standard hemofiltration
cartridge seeded with approximately 108 renal tubule
cells which grow in confluentmonolayers along the inner
surface of the fibers (41–45).
Functional Characteristics of the Renal Assist
Device (RAD)
In vitro studies of this renal tubule assist device have
demonstrated that the cells retain differentiated active
transport properties, differentiated metabolic activities,
and important endocrine processes (Table 1). Addi-
tional studies have shown that the RAD, when incorpo-
rated in series with a hemofiltration cartridge in an
Fig. 1. Schematic representation of the sequelae of inflamma-
tory dysregulation in acute kidney injury (AKI) and end-stage
renal disease (ESRD). The intervention of renal proximal tubule
cell therapy, renal bio-replacement, may interrupt the pathophysi-
ologic spiral that leads to death in AKI, and may possibly inter-
rupt the chronic proinflammatory state of patients with ESRD.
Fig. 2. Advantages of renal bio-replacement therapy compared with the current treatment. Renal bio-replacement therapy replicates
the structure and complete function of the nephron and provides more complete renal replacement therapy.
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extracorporeal blood perfusion circuit, replaces filtra-
tion, transport, metabolic, and endocrine functions of
the kidney in acutely uremic dogs (42). RADs consist-
ing of either human or porcine cells have been success-
fully fabricated and tested (43).
Renal Cell Therapy in Animal Model of AKI
and Sepsis
Our recent studies have demonstrated that renal bio-
replacement therapy with the RAD ameliorates endo-
toxin or bacterial septic shock in acutely uremic animals.
Nephrectomized Mongrel dogs treated with continuous
venovenous hemofiltration (CVVH) and either a RAD
or sham cartridge were given endotoxin to simulate
gram-negative septic shock (44). Mean peak levels of an
anti-inflammatory cytokine, IL-10, and mean arterial
pressures (MAP) were found to be significantly higher in
cell-treated animals. To further assess the effect in ARF
with bacterial sepsis, dogs were nephrectomized and
48 hours later administered intraperitoneally with Esc-
herichia coli (45). Immediately after bacteria administra-
tion, the animals were placed in a CVVH circuit with
either a RAD or a sham cartridge. RAD treatment
maintained better cardiovascular performance, as deter-
mined by MAP and cardiac output, for longer periods
than sham RAD therapy. All sham animals expired
within 2–10 hours after bacteria administration,
whereas all cell RAD-treated animals survived greater
than 10 hours. Levels of IL-10, an anti-inflammatory
cytokine, were significantly elevated in the RAD group,
and a significant correlation was observed between the
rise in plasma IL-10 levels and the decline in MAP. The
RAD maintained renal metabolic activity throughout
the septic period. In another study, pigs with normal kid-
ney function were administered E. coli intraperitoneally
(46). One hour later, the animals were placed in a CVVH
circuit containing either a RAD or a sham cartridge. All
animals developed ARF with anuria within 2–4 hours
after bacteria administration. RAD treatment main-
tained better cardiovascular performance, as determined
by cardiac output and renal blood flow, for longer peri-
ods than sham therapy. Consistently, the RAD group
survived longer than the controls (10  2 hours versus
5  1 hour, respectively). RAD treatment was associ-
ated with significantly lower plasma circulating levels of
IL-6, a proinflammatory cytokine, and interferon-c.
These data demonstrate that septic shock results in early
ARF and that renal bio-replacement therapy improves
the cardiovascular performance associated with changes
in cytokine profiles and confers a significant survival
advantage.
Clinical Experiences of Renal Cell Therapy in
Critically Ill Patients with AKI
The Food andDrugAdministration (FDA) approved
an Investigational New Drug application to study the
RAD containing human cells in patients with ATN
receivingCVVH.Human kidney cells were isolated from
kidneys donated for cadaveric transplantation but found
unsuitable for this purpose because of anatomic or fibro-
tic defects. The initial results in the first 10 treated
patients demonstrated that the RAD can be delivered
safely for up to 24 hours (47). Cardiovascular stability
was maintained, and increased native renal function, as
determined by elevated urine outputs, temporally corre-
lated with RAD treatment. The cells demonstrated dif-
ferentiated metabolic and endocrinologic activity in this
ex vivo treatment. GSH degradation and endocrinologic
conversion of 25-OH-D3 to 1,25-(OH)2-D3 by the RAD
tubule cells were demonstrated. All 10 patients were crit-
ically ill with AKI and MOF, with predicted hospital
mortality rates between 80% and 95%. One patient
expired within 12 hours after RAD treatment following
his family’s request to withdraw ventilatory life support.
Another expired after a surgical catastrophe, toxic
megacolon, required discontinuation of RAD treatment
after only 12 hours. Of the remaining eight patients, six
survived past 28 days with renal function recovery.
Plasma cytokine levels suggest that RAD therapy pro-
duces dynamic and individualized responses in patients
depending on their unique pathophysiologic conditions.
For the subset of patients who had excessive proinflam-
matory levels, RAD treatment resulted in significant
declines in granulocyte-colony stimulating factor, IL-6,
IL-10, and especially IL-6 ⁄ IL-10 ratios, suggesting a
greater decline in IL-6 relative to IL-10 levels and a less
proinflammatory state. Subsequently, a Phase II, ran-
domized, controlled, open-label trial involving 58
patients who had AKI and required continuous renal
replacement therapy (CRRT) was carried out at 12
clinical sites (48). Despite the critical nature and life-
threatening illnesses of the patients enrolled in this study,
the addition of the RAD toCVVH resulted in a substan-
tive clinical impact on survival compared with a conven-
tional CRRT group. RAD treatment for up to 72 hours
promoted a statistically significant survival advantage
over 180 days of follow-up in intensive care unit (ICU)
patients with AKI and demonstrated an acceptable
TABLE 1. In vitro and ex vivo properties of renal tubule cell assist device
Transport Metabolic Endocrinologic
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safety profile. Cox proportional hazards model sug-
gested that the risk of death was approximately 50% of
that observed in the CRRT-alone group (Fig. 3). A
follow-up Phase IIb study to evaluate a commercial
manufacturing process was not completed owing to dif-
ficulties with the manufacturing process and clinical
study design. This approach will be further evaluated
when an improved scale-up manufacturing process is
established.
Renal Bio-Replacement Therapy for ESRD
Amajor disease process that increases the accelerated
morbidity andmortality of ESRDpatients is generalized
atherosclerosis. Recent literature has shown an impor-
tant role for free-radical-induced oxidation of lipopro-
teins in atheroma formation (49). Renal tubule cells are
critical in maintaining the circulating antioxidant com-
pounds of the body (28), including the plasma levels of
GSH and its peroxidases, some of the most important
free-radical-scavenging substances in the blood. The
replacement of these key moieties by use of the RAD
may significantly alter the accelerated atherogenesis in
ESRD patients. The use of renal tubule cells in a chronic
cell therapy device to produce 1,25(OH)2-D3, which is
regulated by normal physiologic parameters such as
parathyroid hormone and inorganic phosphate levels,
would provide a long-term treatment program to mini-
mize the progression of renal osteodystrophy. Finally,
the ability of renal proximal tubules cells to take up and
catabolize b2-microglobulin provides an opportunity to
treat the subset of patients who develop dialysis-related
amyloidosis secondary to high circulating levels of b2-
microglobulin (50). These are just a few examples of the
commonly associated morbidity of patients on chronic
renal substitution therapy and the potential for RAD
treatment to improve these pathophysiologic disease
processes.
Novel Immunomodulatory Device: Selective
Cytopheretic Inhibitory Device (SCD)
Leukocytes, especially neutrophils, are major contrib-
utors to the pathogenesis and progression of many clini-
cal inflammatory disorders, including SIRS, sepsis,
ischemia ⁄ reperfusion injury, and adult respiratory dis-
tress syndrome (ARDS) (51,52). A large number of ther-
apeutic approaches are under investigation to limit the
activation and tissue accumulation of leukocytes at
sites of inflammation to minimize tissue destruction and
disease progression. For example, cardiopulmonary
bypass (CPB) is a strong inducer of SIRS, with activa-
tion of complement and coagulation systems and stimu-
lation of cytokine production, and lung and kidney
damage can be ameliorated during CPB surgery with the
use of leukocyte depletion filters (53). Disruption of the
activation process of circulating leukocytes may limit
microvascular damage and multiorgan dysfunction. We
have developed a synthetic membrane device with the
ability to bind and inhibit activated neutrophils along a
continuous renal replacement extracorporeal circuit.
This device, called an SCD, improved septic shock
survival times in preclinical animal models (54) and
improved the survival outcome of ICU patients with
MOF in an exploratory, randomized, blinded, multi-
center trial (55).
Conclusion
Formany decades, dialysis has benefited both chronic
and acute renal failure patients. However, further devel-
opment of this approach, which is based solely on water
and solute removal, cannot be expected to yield further
therapeutic advantage in terms of reducing morbidity
and improving survival in either acute or chronic dis-
eases. We have recently developed a cell therapy device
containing living animal or human renal tubule cells.We
have confirmed its viability and functionality in in vitro
and large animal studies, and recently demonstrated its
therapeutic benefits in a series of FDA-approved multi-
center human trials.
Our research group is now focused on the role of
kidney as an immunomodulatory organ and the
possibility of renal bio-replacement therapy for the
systemic treatment of inflammatory dysregulation.
The RAD appears to influence systemic leukocyte
activation and the balance of inflammatory cyto-
kines, and may alter the proinflammatory state of
AKI and ESRD and, ultimately, improve the mor-
bidity and mortality of these disorders. In addition,
a novel synthetic membrane device, the SCD, mimics
immunomodulation and duplicates RAD efficacy.
We believe both devices will become comprehensive
treatments to more fully replace renal functions and
correct inflammatory imbalance in patients with
acute or chronic renal disorders, especially those
patients with critical illnesses such as sepsis, SIRS, or
MOF. The future focus of renal care must go
beyond replacement of the small-solute clearance
function of the kidney.
Fig. 3. Kaplan–Meier estimates of survival of patients in the
renal tubule cell assist device (RAD) and conventional continu-
ous renal replacement therapy (CRRT) groups. The mortality
rate at day 28 was 61% in the CRRT group compared with 33%
in the RAD group, and at day 180 mortality was 76.5% in the
CRRT group compared with 50% in the RAD group. The haz-
ard ratio for death in the RAD group compared with the CRRT
group adjusted for disease cause was 0.481 (95% confidence
interval, 0.23–0.99). Adapted from Tumlin et al. (48).
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